INTERSYN

Intersyn is an early-stage biotechnology company focused on developing novel therapeutics to restore and maintain synaptic function in the brain. Founded by Nobel Laureate Thomas Südhof, the company leverages world-leading expertise in synaptic biology to address the molecular drivers of neurodegenerative and neuropsychiatric diseases. Their approach targets the complex protein networks that govern neuronal connectivity, aiming to prevent or reverse the synaptic loss that characterizes conditions like Alzheimer's and Parkinson's. Intersyn operates primarily in stealth mode, advancing a pipeline of programs designed to preserve cognitive health through the modulation of synaptic integrity.